Feedback / Questions
AL01211 - AceLink Therap
https://www.businesswire.com/news/home/20250207924380/en/AceLink-Therapeutics-Presents-Interim-Results-from-a-Phase-2-Trial-of-the-GCS-Inhibitor-AL01211-in-Treatment-Na%C3%AFve-Classic-Male-Fabry-Disease-Patients-at-the-WORLD-Symposium-2025
Feb 7, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next